The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.

Abstract

The participation of herpes simplex virus (HSV) glycoproteins in T cell-mediated lysis of HSV-infected syngeneic target cells was examined by using a temperature sensitive (ts) mutant defective in glycoprotein synthesis at the nonpermissive temperature (39 degrees C), and 2-deoxy-D-glucose and tunicamycin, known inhibitors of both HSV replication and glycoprotein synthesis in HSV-infected cells. Lymphocytes cytotoxic for HSV-infected cells lysed C57BL/6 Wt-3 cells infected with the mutant, ts A1, at 39 degrees C less efficiently than at 33 degrees C. Treatment of HSV-infected C57BL/6 Wt-3 cells with 1% 2-deoxy-D-glucose for 14 hr reduced their susceptibility to T cell-mediated lysis by 73% in the 51Cr release assay. Treatment of HSV-infected C57BL/6 Wt-3 cells with 0.2 microgram/ml tunicamycin for 14 hr reduced their susceptibility to T cell-mediated lysis by 78% in the 51Cr release assay. The reduction in T cell-mediated lysis by 2 deoxy-D-glucose and tunicamycin was found not to be due to the effects of the compounds on the H-2 antigens. We conclude that HSV specific glycoproteins are involved in T cell-mediated lysis of HSV-infected cells.

No protection seen on challenge with live virus after single intranasal immunization with heat inactivated virus in murine model of EHV-1 infection

“…Studies in mice predict the similar patten in human. 41,44 After primary infection of herpes simplex virus infection there is a strong immune response and human subjects are not easy to be re-infected with the virus. Similarly, latently infected subjects are protected from a second infection or reinfection from HSV, but virus reactivate and cause disease.…”